SOX13 and neoplasm: The tumor growth inhibition treatment/control (T/C) ratios of IKE on tumors from SNU-668-NC cell-derived xenografts (CDX) and from SNU-668-SOX13-CDX tumors were 70.72 ± 13.81% and 31.88 ± 8.73%, respectively (Fig. 3F, left).